3.5 ACOX1-specific inhibitors improve the efficacy and reduce the toxicity of OCA via inhibiting IL-β and α-SMA pathways in NAFLD treatment. This evidence concerns the gene ACTA1 and metabolic dysfunction-associated steatotic liver disease.